• Je něco špatně v tomto záznamu ?

Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation

V. Sládková, O. Dammer, B. Kratochvíl,

. 2016 ; 105 (10) : 3136-3142. [pub] 20160810

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017097

Tenofovir disoproxil fumarate (TDF, form I) is an orally delivered pharmaceutical salt used for the treatment of HIV and chronic hepatitis, which acts as an inhibitor of nucleotide reverse transcriptase. There are many solid forms of TDF described in the literature; 2 of them were identified in the drug products: form I and form A. It seems that during formulation, the active pharmaceutical ingredient undergoes partial to total conversion of TDF form I to TDF form A. The goals of this study were to investigate when and why did the conversion occur and whether the conversion could be avoided and how. The influence of pH and possible interaction with excipients were studied. The conditions enabling using wet granulation in technology while preventing the undesired conversion were found. The stabilization was achieved either by replacement of used disintegrants or by acid addition to the current composition of formulation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017097
003      
CZ-PrNML
005      
20230712135335.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.xphs.2016.07.002 $2 doi
035    __
$a (PubMed)27522525
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sládková, Veronika $u Department of Solid State Chemistry, University of Chemistry and Technology Prague, Prague 6, Czech Republic 16628; Solid State Department, Zentiva, k.s., Prague 10, Czech Republic 10237. Electronic address: sladkovv@vscht.cz.
245    10
$a Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation / $c V. Sládková, O. Dammer, B. Kratochvíl,
520    9_
$a Tenofovir disoproxil fumarate (TDF, form I) is an orally delivered pharmaceutical salt used for the treatment of HIV and chronic hepatitis, which acts as an inhibitor of nucleotide reverse transcriptase. There are many solid forms of TDF described in the literature; 2 of them were identified in the drug products: form I and form A. It seems that during formulation, the active pharmaceutical ingredient undergoes partial to total conversion of TDF form I to TDF form A. The goals of this study were to investigate when and why did the conversion occur and whether the conversion could be avoided and how. The influence of pH and possible interaction with excipients were studied. The conditions enabling using wet granulation in technology while preventing the undesired conversion were found. The stabilization was achieved either by replacement of used disintegrants or by acid addition to the current composition of formulation.
650    _2
$a látky proti HIV $x chemie $x metabolismus $7 D019380
650    _2
$a příprava léků $x metody $7 D004339
650    _2
$a stabilita léku $7 D004355
650    _2
$a pomocné látky $x chemie $x metabolismus $7 D005079
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a tenofovir $x chemie $x metabolismus $7 D000068698
650    _2
$a difrakce rentgenového záření $x metody $7 D014961
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dammer, Ondřej $u Solid State Department, Zentiva, k.s., Prague 10, Czech Republic 10237. $7 xx0303489
700    1_
$a Kratochvíl, Bohumil $u Department of Solid State Chemistry, University of Chemistry and Technology Prague, Prague 6, Czech Republic 16628.
773    0_
$w MED00002895 $t Journal of pharmaceutical sciences $x 1520-6017 $g Roč. 105, č. 10 (2016), s. 3136-3142
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27522525 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20230712135337 $b ABA008
999    __
$a ok $b bmc $g 1300721 $s 1013937
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 105 $c 10 $d 3136-3142 $e 20160810 $i 1520-6017 $m Journal of pharmaceutical sciences $n J Pharm Sci $x MED00002895
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...